About Pricing FAQs Blog

Loading clinical trials...

Clareo Health Find Clinical Trials →

© 2026 Clareo Health. All rights reserved.

Kidney Disease Clinical Trials in Los Angeles | 177 Studies | Clareo Health

Clinical Trials Kidney DiseaseLos Angeles

Kidney Disease Clinical Trials in Los Angeles

Find 177 clinical trials for kidney disease near Los Angeles, California. Connect with research centers in your area.

All Kidney Disease trials nationwide All trials in Los Angeles

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 61-80 of 177 trials

ACTIVE_NOT_RECRUITINGPHASE1< 1 mile

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pancreatic CancerBreast CancerGastric Cancer+13 more

NGM Biopharmaceuticals, Inc130 participantsStarted Mar 2022

Gilbert, Arizona, United States • Los Angeles, California, United States • Sarasota, Florida, United States +6 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

MesotheliomaGlioblastomaRenal Cell Carcinoma+12 more

NGM Biopharmaceuticals, Inc179 participantsStarted Jun 2021

Los Angeles, California, United States • Newport Beach, California, United States • Santa Monica, California, United States +24 more locations

Kidney Disease Trials in Other Cities

New York Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

COMPLETEDPHASE2< 1 mile

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03219333

This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body. This clinical trial will enroll patients who were previously treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). Some CPIs have been approved for the treatment of urothelial cancer. This study will test if the cancer shrinks with treatment. This study will also look at the side effects of the drug. A side effect is a response to a drug that is not part of the treatment effect. Patients who sign up for this trial must also fall into one of these categories: * Patients have already received treatment with platinum-containing chemotherapy * Patients have never received platinum-containing treatment and are not eligible for treatment with cisplatin.

Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic Neoplasms+4 more

Astellas Pharma Inc219 participantsStarted Oct 2017

Anchorage, Alaska, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +78 more locations

COMPLETEDPHASE2< 1 mile

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

NCT00378482

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Colorectal NeoplasmsMelanomaProstatic Neoplasms+3 more

AstraZeneca37 participantsStarted Mar 2007

Los Angeles, California, United States • Tampa, Florida, United States • Ann Arbor, Michigan, United States +3 more locations

COMPLETEDPHASE3< 1 mile

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

NCT03849118

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.

Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals (Innovations) Pty Limited300 participantsStarted Aug 2019

Duarte, California, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +28 more locations

TERMINATED< 1 mile

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

NCT02115503

The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic rejection episodes in renal transplant subjects. 162 renal transplant subjects will receive IVIg 5% at 2gm/kg/month for 6 months and be followed for 3 years.

Renal Transplant Recipients With Anti-HLA Antibodies

Databean52 participantsStarted Jul 2014

Los Angeles, California, United States • Sacramento, California, United States • Aurora, Colorado, United States +5 more locations

COMPLETEDPHASE2< 1 mile

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200

OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites. The study aims are to evaluate the safety and efficacy of OCE-205 at various doses. Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.

CirrhosisAscitesHepatorenal Syndrome+1 more

Ocelot Bio, Inc47 participantsStarted Apr 2022

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +20 more locations

COMPLETED11 miles

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

NCT03133286

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.

Radiation TherapyCancerCancer of Anus+16 more

DxTerity Diagnostics16 participantsStarted Apr 2017

Compton, California, United States • Bradenton, Florida, United States • Fort Myers, Florida, United States +1 more locations

COMPLETEDNA14 miles

Using Virtual Reality (VR) Models for Preoperative Planning

NCT03334344

A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic partial nephrectomy) and improved patient care.

Kidney CancerRenal Cell Carcinoma

Ceevra, Inc.92 participantsStarted Oct 2017

Santa Monica, California, United States • Jacksonville, Florida, United States • New York, New York, United States +3 more locations

COMPLETEDPHASE116 miles

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

NCT03829111

This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced). CBM588 is a probiotic that may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CBM588, nivolumab, and ipilimumab may work better in treating patients with kidney cancer.

Advanced Renal Cell CarcinomaClear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma+3 more

City of Hope Medical Center30 participantsStarted May 2019

Duarte, California, United States

TERMINATEDPHASE116 miles

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 \[PD-1\] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more

Pfizer13 participantsStarted Oct 2021

Duarte, California, United States • New York, New York, United States • New York, New York, United States

TERMINATEDPHASE321 miles

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05356403

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of oral difelikefalin administered as a 1 mg tablet once daily compared to placebo in reducing the intensity of itch in advanced chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study is comprised of an Efficacy Assessment Phase and a Long-term Extension Phase. The Efficacy Assessment Phase includes a double-blind 12-week Treatment Period (Treatment Period 1), and the Long-term Extension Phase includes a double-blind Treatment Period (Treatment Period 2) of up to 52 weeks.

Chronic Kidney DiseasesPruritus

Cara Therapeutics, Inc.105 participantsStarted Aug 2022

Northridge, California, United States • Miami, Florida, United States • Miami Lakes, Florida, United States +72 more locations

COMPLETEDNA22 miles

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.

Acute Myeloid LeukemiaBrain GlioblastomaEstrogen Receptor Negative+64 more

Stanford University128 participantsStarted Aug 2017

Fullerton, California, United States

COMPLETED49 miles

A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life

NCT04034992

DISCOVER CKD is an international observational cohort study in patients with CKD, comprising both prospective and retrospective patient cohorts. The study does not attempt to test any specific a priori hypotheses, is largely descriptive, and utilises data collected only under conditions of routine clinical care.

Chronic Kidney Disease

AstraZeneca1,052 participantsStarted Sep 2019

Riverside, California, United States • San Francisco, California, United States • Sanford, Florida, United States +40 more locations

ENROLLING_BY_INVITATION320 miles

Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration

NCT05161078

To date, little knowledge exists related to the use of hemodialysis (HD) in infants and has been limited to mainly single center studies. The CARPEDIEM (CArdio-Renal PEdiatric Dialysis Emergency Machine) device, which can be used to provide hemodialysis in infants, has been launched in the United States. This study/registry is designed to obtain data on critically ill infants who require HD using the CARPEDIEM device to understand the indications for initiation, best practice in prescribing and performing treatment, expected treatment course, and outcomes of a dedicated infant continuous renal replacement therapy (CRRT) machine.

Acute Kidney InjuryChronic Kidney DiseasesRenal Dialysis

Children's Hospital Medical Center, Cincinnati1,000 participantsStarted Dec 2021

Palo Alto, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +6 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2320 miles

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more

23andMe, Inc.141 participantsStarted Dec 2021

Palo Alto, California, United States • Atlanta, Georgia, United States • Detroit, Michigan, United States +10 more locations

TERMINATEDPHASE1320 miles

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric Cancer+9 more

ADC Therapeutics S.A.78 participantsStarted Nov 2018

Palo Alto, California, United States • New Haven, Connecticut, United States • Portland, Oregon, United States +6 more locations

ACTIVE_NOT_RECRUITINGNA826 miles

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

NCT04252573

Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex Abdominal Aortic Aneurysms.

1 Paravisceral Abdominal Aortic Aneurysm2 Juxtarenal Abdominal Aortic Aneurysm3 Pararenal Abdominal Aortic Aneurysm+1 more

Endologix13 participantsStarted Jun 2020

Huntsville, Alabama, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +5 more locations

COMPLETEDPHASE1826 miles

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

NCT04540705

The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.

Renal Cell Carcinoma

Bristol-Myers Squibb30 participantsStarted Sep 2020

Springdale, Arkansas, United States • Louisville, Kentucky, United States • St Louis, Missouri, United States +36 more locations

ACTIVE_NOT_RECRUITINGPHASE2/PHASE3960 miles

Communication During Hospitalization About Resuscitation Trial

NCT02984124

This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.

Severe Life-limiting COPDSevere Life-limiting Heart FailureSevere Life-limiting Cirrhosis+3 more

University of Vermont182 participantsStarted Dec 2016

Chapel Hill, North Carolina, United States • Charleston, South Carolina, United States • Burlington, Vermont, United States +1 more locations

PreviousPage 4 of 9Next

Other Conditions in Los Angeles

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia